In a retrospective study of locally advanced PCA pts from MDACC, pts who rcvd induction gemcitabine f/b CRT had longer MS than pts that had initial CRT (12 mos vs. 8 mos). They hypothesize that induction chemo may select for pts that benefit from CRT. (KrishnanS et al., Cancer 2007)